Appsens AS has entered into a strategic collaboration agreement with Stevn Technologies AB to roll out the ECG247 solution in the Danish and Finnish markets. This marks a significant milestone in our ambition to become the leading Nordic provider of mobile heart rhythm monitoring.
Following solid growth in Norway, we are now taking the next step to strengthen our presence across the entire Nordic region. Through our partnership with Stevn Technologies AB, we gain a partner with deep insight into the medical technology markets of both Denmark and Finland.
Strengthening Accessibility Across the Nordics
The collaboration with Stevn Technologies will ensure that both public and private healthcare providers in our neighboring countries gain easy access to ECG247. The goal is to facilitate faster and more efficient diagnostics of heart rhythm disorders for patients throughout the Nordic region.
«We are very pleased to have Stevn Technologies on board. Their expertise in implementing new medical technology is exactly what we need to succeed with our venture in Denmark and Finland,» says Tord Ytterdahl, CEO of Appsens AS.
A Strategic Match for Growth
Stevn Technologies AB specializes in bringing innovative healthcare solutions to market. They see significant untapped potential for more efficient heart rhythm screening and view ECG247 as a key component in modernizing cardiological follow-up.
Under this agreement, Stevn Technologies will handle operational marketing and local sales efforts. This ensures that we can provide high-quality local support to clinics and hospitals looking to adopt the solution in these new markets.
With this expansion, Appsens takes another major step toward its goal of making advanced cardiac diagnostics accessible to everyone—regardless of where they live.
